Loading…
← CockpitCompetitor Analysis › 688105.SS Nanjing Vazyme Biotech Co., Ltd. Class AOpen in the cockpit ↗

Nanjing Vazyme Biotech Co., Ltd. Class A688105.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese life-science reagent maker producing enzymes, molecular-biology kits and reagents for research and diagnostics.

≈ A Chinese life-science reagent supplier akin to New England BiolabsMomentum strong 79
Mkt cap
$1.42B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$37.0M
20-day average traded
Fwd P/E
137.8×
forward earnings
ROIC−WACC
-6.5 pp
WACC 10.0%
Hurdle
+42 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥18.80
1D-5.5%
1W-19.0%
1M-18.4%
3M-23.0%
6M+25.5%
YTD+22.1%
1Y+6.2%
ATR %9.6%
52w lowhigh35.5% off high

What Nanjing Vazyme Biotech does

Chinese life-science reagent maker producing enzymes, molecular-biology kits and reagents for research and diagnostics.

Sells enzymes, kits and reagents repeatedly to labs, so revenue follows research and testing activity, with purchases recurring once a lab has validated a product. COVID testing boosted demand for its raw materials during the pandemic, and that demand has since faded, leaving research and diagnostics customers as the base.

In one line: A Chinese life-science reagent supplier akin to New England Biolabs.

Products and services

  • Enzymes (e.g., PCR/qPCR)
  • Molecular cloning/library-prep kits
  • Diagnostic reagent raw materials

Customers

  • Research institutes/universities
  • IVD/diagnostics companies
  • Biotech labs

Where it sits in the supply chain

  • Health Care
  • Life science tools
  • Molecular biology reagents

What could go right

  • China life-science research/IVD spending growth
  • Import substitution for lab reagents

What could go wrong

  • Multinational reagent-maker competition
  • Research funding cyclicality

Moat: narrow (process know-how, brand, IP / patents). Established quality/brand in domestic molecular-biology reagents, competing against multinational incumbents.

Headquarters: Nanjing, China · Employees: 3,002

Named competitors

Nanjing Vazyme Biotech at a glance

Size Nanjing Vazyme Biotech (688105.SS) is a China Health Care company (Biotechnology) with a market value of $1.42B, the 1587th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.80 on 18 Nov 2026.

Performance Over six months the shares gained 25.5%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 15.8% over the last twelve months (peer median +26.4%); the operating margin is -4.6% (peer median -295.1%).

Valuation It trades at 137.8× forward earnings against a peer median of 31.5× (2nd most expensive of 5).

Price implies For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.5 points below its cost of capital (10.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026688105.SS 117Peer median 79
Six months, rebased to 100: Nanjing Vazyme Biotech against the median of its 20 peers (local-currency closes).

Nanjing Vazyme Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.56BCN¥1.37BCN¥1.37BCN¥1.28BCN¥3.55B
Revenue growth—0%+7%-64%—
Gross profitCN¥1.18BCN¥872MCN¥862MCN¥823MCN¥2.40B
EBITDAn/aCN¥96.0MCN¥97.3M-CN¥44.6MCN¥1.02B
Net incomeCN¥993,147-CN¥16.6M-CN¥18.1M-CN¥71.0MCN¥594M
Free cash flowCN¥303MCN¥249M-CN¥32.0M-CN¥34.5M-CN¥166M
Capital expenditureCN¥30.0MCN¥47.4MCN¥74.9MCN¥233MCN¥963M
Total debtCN¥857MCN¥842MCN¥755MCN¥1.29BCN¥484M

Quarterly statements and history in the cockpit →

Nanjing Vazyme Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%QUREABSIIMCRANAB688765URGNRAPP26376881854588MSB087010KRSA688105.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Nanjing Vazyme Biotech is the large dot.

Fundamentals: revenue growth against valuation

+50%+100%+150%0×100×200×ANABURGN2637688185688105.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanjing Vazyme Biotech is the large dot.

Nanjing Vazyme Biotech competitors and peer comparison

Head to head with its named competitors (688105.SS vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Nanjing Vazyme Biotech 688105.SS$1.42B+25%+16%-5%137.8×39.4%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Nanjing Vazyme Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Vazyme Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688105.SSPeer medianRank in peer set
1-month return-18.4%-10.2%5th lowest of 21
6-month return+25.5%-20.3%4th highest of 20
Distance from 52-week high-35.5%-47.0%6th highest of 21
Revenue growth (TTM)+15.8%+26.4%8th lowest of 17
Operating margin-4.6%-295.1%5th highest of 18
Forward P/E137.8×31.5×2nd most expensive of 5
Growth the price implies (Req g, 7 yrs)39.4%n/a—
Growth delivered (Del g)-2.5%n/a—
Hurdle (Req g minus delivered)+41.9 ppn/a—
ROIC minus cost of capital-6.5 pp-19.2 pp3rd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%199.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a

Questions

Who are Nanjing Vazyme Biotech's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Takara Bio (private or unlisted). The cockpit's measured peer set (industry) also includes uniQure (QURE), Absci (ABSI), Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR), AnaptysBio (ANAB), Wuhan Healthgen Biotechnology (688765.SS), UroGen Pharma (URGN).
Is Nanjing Vazyme Biotech expensive compared with its peers?
On forward p/e it trades at 137.8× against a peer median of 31.5×, 2nd most expensive of 5 in its peer set. For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Nanjing Vazyme Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned +25.5% against -20.3% for the median peer; over one year +6.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.